Please use this identifier to cite or link to this item:
Title: Assessment and Management of Newly Diagnosed Classical Hodgkin Lymphoma: A Consensus Practice Statement from the Australasian Lymphoma Alliance.
Austin Authors: Cochrane, T;Campbell, B A;Gangatharan, S A;Latimer, M;Khor, Richard ;Christie, Drh;Gilbertson, M;Ratnasingam, S;Palfreyman, E;Lee, H P;Trotman, J;Hertzberg, M;Dickinson, M
Affiliation: Department of Clinical Pathology, University of Melbourne, Melbourne, Victoria
Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia
Sir Peter MacCalllum Department of Oncology, the University of Melbourne, Victoria, Australia
Dept of Haematology, Gold Coast University Hospital, QLD
Griffiths University, QLD
Fiona Stanley Hospital, Perth, WA
University of Western Australia, WA
Department of Radiation Oncology, Melbourne, Victoria
Austin Health
Genesiscare, Gold Coast, QLD, Australia
Monash Health, Melbourne, Victoria, Australia
School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Dept of Haematology and Oncology, Western Health, Melbourne, Victoria, Australia
Andrew Love Cancer Centre, University Hospital Geelong, Melbourne, Victoria, Australia
Flinders Medical Centre, Adelaide, South Australia
Concord Repatriation General Hospital, Sydney, New South Wales, Australia
University of Sydney, Sydney, New South Wales, Australia
Department of Haematology, Prince of Wales Hospital, Sydney, New South Wales, Australia
University of NSW, Sydney, New South Wales, Australia
ACT Pathology and Canberra Hospital, ACT
Royal Darwin Hospital, Northwest Territories, Canada
Bond University, Gold Coast, QLD, Australia
Issue Date: 9-Sep-2021 2021-09-09
Publication information: Internal Medicine Journal 2021; online first: 9 September
Abstract: The management of Hodgkin Lymphoma (HL) has undergone significant changes in recent years. Due to the predilection of HL to affect younger patients, balancing cure and treatment related morbidity is a constant source of concern, for physicians and patients alike. PET adapted therapy has been developed for both early and advanced stage HL to try and improve the outcome of treatment, whilst minimising toxicities. The aim of this review is to digest the plethora of studies recently conducted and provide some clear, evidence-based practice statements to simplify the management HL. This article is protected by copyright. All rights reserved.
DOI: 10.1111/imj.15503
ORCID: 0000-0002-2668-1399
Journal: Internal Medicine Journal
PubMed URL: 34505342
Type: Journal Article
Subjects: HL
Hodgkin Lymphoma
PET adapted
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jun 6, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.